The National Committee for Quality Assurance has announced the launch of its newest evaluation program, which creates a roadmap for how sites delivering intermittent or outpatient treatment — but do not act as a primary care provider for a majority of its patients — can fit into the medical home neighborhood.
The supplement industry on Wednesday called into question the validity of the New York Attorney General's investigtation into botanical dietary supplements with a white paper that outlines the potential shortfalls of the testing methodology used.
Pain is proving to be a significant factor when it comes to sleeping patterns of Americans, according to a new poll by the National Sleep Foundation. Those suffering with chronic pain reported an average 42 minute sleep debt, whereas Americans who have experienced acute pain within the past week report a deficit of 14 minutes.
The U.S. prestige beauty industry reached $11.2 billion and grew 3% in dollar sales in 2014, compared with 2013, according to global information company the NPD Group, with makeup experiencing the healthiest gain, 6%, while fragrance dollars grew 2% and skincare increased by 1%.
The Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology released a draft roadmap toward the safe and secure exchange and use of electronic health information.
Several of the nation’s largest healthcare systems and payers on Tuesday announced a powerful new private-sector alliance dedicated to accelerating the transformation of the U.S. healthcare system to value-based business and clinical models.
A new study from the National Institutes of Health, Office of Dietary Supplements, found a significant association in reducing death from cardiovascular disease among multivitamin users vs. non-users, when the supplements were taken for three or more years.
With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.
The Council for Responsible Nutrition expressed its support in response to a study, “Effect of Maternal Multiple Micronutrient vs Iron–Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh.”
The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.